A Phase I, Open-Label Study to Assess the Effect of Dosing AZD6244 HydSulfate [AZD-6244] in the Presence and Absence of Food in Patients With Advanced Solid Malignancies.

Trial Profile

A Phase I, Open-Label Study to Assess the Effect of Dosing AZD6244 HydSulfate [AZD-6244] in the Presence and Absence of Food in Patients With Advanced Solid Malignancies.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Oct 2014

At a glance

  • Drugs Selumetinib (Primary)
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 01 Dec 2011 Results published in Cancer Chemotherapy and Pharmacology.
    • 23 Nov 2010 New source identified and integrated (United Kingdom Clinical Research Network).
    • 12 May 2010 Actual patient number (30) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top